BioLine RX News

Notizie Eulerpool BioLine RX

Notizie Titolo BioLine RX

BioLine RX è monitorato da giornalisti e investitori in tutto il mondo. Qui raccogliamo le ultime notizie su BioLine RX.

• 20 marzo·

  Benzinga
  Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings
• 26 febbraio·

  Benzinga
  12 Health Care Stocks Moving In Thursday's After-Market Session
• 23 febbraio·

  Benzinga
  Arbitrator Issues Final Award To BioLineRx, Denies All Claims By Biokine Therapeutics; Biokine To Pay Expenses And Legal Fees
• 29 novembre·

  Yahoo
  BioLine Rx Ltd (BLRX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
• 25 novembre·

  Yahoo
  BLRX: Stem Cell Mobilization Presentation at ASH
• 24 novembre·

  Yahoo
  BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
• 24 novembre·

  SeekingAlpha
  BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript
• 18 novembre·

  Yahoo
  BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
• 17 novembre·

  Yahoo
  BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
• 30 settembre·

  Yahoo
  BLRX: A Venture into GBM
• 29 settembre·

  SeekingAlpha
  BioLineRx Ltd. (BLRX) Investor Call (Transcript)
• 29 settembre·

  SeekingAlpha
  BioLineRx Ltd. - Special Call
• 14 agosto·

  SeekingAlpha
  BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript
• 14 agosto·

  Benzinga
  Earnings Scheduled For August 14, 2025
• 3 luglio·

  Yahoo
  H.C. Wainwright Reaffirms Buy on BioLineRx Ltd. (BLRX) After ASCO 2025
• 17 giugno·

  Benzinga
  Where BioLine Rx Stands With Analysts
• 9 giugno·

  Benzinga
  12 Health Care Stocks Moving In Monday's Pre-Market Session
• 31 maggio·

  Yahoo
  BioLineRx upgraded to Buy from Hold at JonesResearch
• 30 maggio·

  Benzinga
  Dow Edges Higher; Dell Shares Fall After Q1 Results
• 30 maggio·

  Yahoo
  BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

Comunicati Stampa Titolo BioLine RX

BioLine RX pubblica regolarmente notizie sul sito web della società rilevanti per gli investitori.

• 18 novembre•

  BioLine RX
  Biolinerx Reports Third Quarter 2021 Financial Results And Provides Corporate Update
• 18 agosto•

  BioLine RX
  BioLine RX Reports Q2 Loss Per Share Of $0.01
• 26 maggio•

  BioLine RX
  Biolinerx Reports Q1 2021 Financial Results
• 4 maggio•

  BioLine RX
  Biolinerx Announces Positive Top-Line Results From Genesis Phase 3 Trial Of Motixafortide In Stem-Cell Mobilization For Autologous Bone Marrow Transplantation In Multiple Myeloma Patients
• 23 febbraio•

  BioLine RX
  Biolinerx Reports Year-End 2020 Financial Results
• 19 gennaio•

  BioLine RX
  Biolinerx Announces $10 Million Bought Deal Offering
• 16 dicembre•

  BioLine RX
  Biolinerx Announces Final Results From Phase 2A Combat/Keynote-202 Triple Combination Study Of Motixafortide
• 23 novembre•

  BioLine RX
  BioLineRx Reports Q3 Loss Per Share $0.02
• 18 novembre•

  BioLine RX
  BiolineRx Announces Initiation Of Phase 1B Clinical Trial In Patients With Acute Respiratory Distress Syndrome Secondary To COVID-19 And Other Respiratory Viral Infections
• 30 ottobre•

  BioLine RX
  Biolinerx Announces Positive Results From Interim Analysis Of Genesis Phase 3 Trial Of Motixafortide In Stem Cell Mobilization
• 6 agosto•

  BioLine RX
  BioLineRx Says On Track To Report Three Significant Data Readouts In Next Few Months
• 20 maggio•

  BioLine RX
  Bioline Rx Ltd Reports Q1 Loss Per Share Of $0.04
• 12 marzo•

  BioLine RX
  Bioline On Track To Report Data From Triple Combination Arm Of Ongoing Mid-stage Trial In Mid-2020